Changing patterns of CAD therapy and hormone usage for women

Cardiology Review

Volumn 22, Issue 3 SPEC. ISS., 2005, Pages 32-39

  Mazzaferri Jr , Ernest L ^a   Limacher, Marian C ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL FUMARATE; CLOPIDOGREL; CONJUGATED ESTROGEN; ESTROGEN; FIBRINOGEN RECEPTOR ANTAGONIST; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NIFEDIPINE; PERINDOPRIL; PLACEBO; PRAVASTATIN; RAMIPRIL; STATIN; TRANDOLAPRIL;

CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; HIGH RISK PATIENT; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; POSTMENOPAUSE; PRACTICE GUIDELINE; REVASCULARIZATION; REVIEW; RISK FACTOR; SUBSTITUTION THERAPY; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 20044364953     PISSN: 10926607     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. American Heart Association. Heart Disease and Stroke Statistics - Update 2004. 2003. Dallas, Texas. Available at: http://www.americanheart.org/ downloadable/heart/1079736729696HDSStats2004UpdateREV3-19-04.pdf. Accessed December 14, 2004.
2. Mosca L, Ferris A, Fabunmi R, et al; American Heart Association. Tracking women's awareness of heart disease: an American Heart Association national study. Circulation. 2004;109(5):573-579.
3. O'Rourke RA, Fuster V, Alexander RW, et al, eds. Hurst's The Heart. 10th ed. New York, NY: McGraw-Hill; 2001.
4. Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill testing in women [published correction appears in J Am Coll Cardiol. 1999;33(1):289]. J Am Coll Cardiol. 1998;32(6):1657-1664.
5. Pepine CJ, Abrams J, Marks RG, et al. Characteristics of a contemporary population with angina pectoris. TIDES Investigators. Am J Cardiol. 1994;74(3):226-231.
6. Ford ES, Giles WH. Changes in prevalence of nonfatal coronary heart disease in the United States from 1971-1994. Ethn Dis. 2003;13(1):85-93.
7. Vaccarino V, Parsons L, Every NR, et al. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med. 1999;341(4):217-225.
8. Cowley MJ, Mullin SM, Kelsey SF, et al. Sex differences in early and long-term results of coronary angioplasty in the NHLBI PTCA Registry. Circulation, 1985; 71(1):90-97.
9. Kelsey SF, James M, Holubkov AL, et al. Results of percutaneous transluminal coronary angioplasty in women. 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation. 1993;87(3):720-727.
10. Bell MR, Hohnes DR Jr, Berger PB, et al. The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty. JAMA. 1993;269(16):2091-2095.
11. Fisher LD, Kennedy JW, Davis KB, et al. Association of sex, physical size, and operative mortality after coronary artery bypass in the Coronary Artery Surgery Study (CASS). J Thorac Cardiovasc Surg. 1982;84(3):334-341.
12. Loop FD, Golding LR, MacMillan JP, et al. Coronary artery surgery in women compared with men: analyses of risks and long-term results. J Am Coll Cardiol. 1983;1(2 pt 1):383-390.
13. Dahlof B, Devereux RB, Kjeldsen SE, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359 (9311):995-1003.
14. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343 (7):475-480.
15. Peterson ED, Lytle BL, Biswas MS, et al. Willingness to participate in cardiac trials. Am J Geriatr Cardiol. 2004;13(1):11-15.
16. Khan IA, Mehta NJ. Initial historical descriptions of the angina pectoris. J Emerg Med. 2002;22(3):295-298.
17. Philpott S, Boynton PM, Feder G, et al. Gender differences in descriptions of angina symptoms and health problems immediately prior to angiography: the ACRE study. Appropriateness of Coronary Revascularisation study. Soc Sci Med. 2001;52(10):1565-1575.
18. Kyker KA, Limacher MC. Gender differences in the presentation and symptoms of coronary artery disease. Curr Women's Health Rep. 2002;2(2):115-119.
19. Murabito JM, Evans JC, Larson MG, et al. Prognosis after the onset of coronary heart disease. An investigation of differences in outcome between the sexes according to initial coronary disease presentation. Circulation. 1993;88(6):2548-2555.
20. Forslund L, Hjemdahl P, Held C, et al. Ischaemia during exercise and ambulatory monitoring in patients with stable angina pectoris and healthy controls. Gender differences and relationships to catecholamines. Eur Heart J. 1998;19(4): 578-587.
21. Shaw LJ, Miller DD, Romeis JC, et al. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. Ann Intern Med. 1994;120(7):559-566.
22. Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TTMI III registry. JAMA. 1996;275(14): 1104-1112.
23. Gibbons RJ, Abrams J, Chatterjee K, et al; American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41(1): 159-168.
24. Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1991; 114(10):835-839.
25. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340(8833):1421-1425.
26. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88(3): 230-235.
27. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;344(8934): 1383-1389.
28. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14): 1001-1009.
29. Sever PS, Dahlof B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
30. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
31. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15):1495-1504.
32. Nissen SE, Tuzcu EM, Schoenhagen P, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-1080.
33. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10): 669-677.
34. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [published corrections appear in N Engl J Med. 2000;342(10):748 and 2000;342(18):1376]. N Engl J Med. 2000;342(3):145-153.
35. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386): 782-788.
36. Braunwald E, Domanski MJ, Fowler SE, et al; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058-2068.
37. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation. 1994; 90(2):762-768.
38. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TTBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol. 1995;25(1):231-238.
39. Braunwald E, Antman EM, Beasley JW, et al; American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina. ACC/AHA2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40(7): 1366-1374.
40. Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med. 1999;341(4):226-232.
41. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials [published correction appears in Lancet. 2002;359(9323):2120]. Lancet. 2002;359(9302):189-198.
42. Hochman JS, McCabe CH, Stone PH, et al. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1997; 30(1):141-148.
43. Jacobs AK, Johnston JM, Haviland A, et al. Improved outcomes for women undergoing contemporary percutaneous coronary intervention: a report from the National Heart, Lung, and Blood Institute Dynamic registry. J Am Coll Cardiol. 2002;39(10):1608-1614.
44. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). Circulation. 1998;98(13):1279-1285.
45. De Luca G, Suryapranata H, Dambrink JH, et al. Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: data from the Zwolle Myocardial Infarction study. Am Heart J. 2004;148(5): 852-856.
46. Antman EM, Anbe DT, Armstrong PW, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110(5):588-636.
47. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991; 20(1):47-63.
48. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-613.
49. Grady D, Herrington D, Bittner V, et al; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) [published correction appears in JAMA. 2002;288(9):1064]. JAMA. 2002; 288(1):49-57.
50. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
51. Manson JE, Hsia J, Johnson KC, et al; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6)523-534.
52. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial JAMA. 2003;289(20):2673-2684.
53. Shumaker SA, Legault C, Rapp SR, et al; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA, 2003;289 (20):2651-2662.
54. Anderson GL, Limacher M, Assaf AR, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
55. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004; 291(1):47-53.
56. FDA News. FDA Approves New Labels for Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women Following Review of Women's Health Initiative Data P03-01 January 8, 2003. Available at http://www.fda.gov/bbs/ topics/NEWS/2003/NEW00863.html. Accessed December 23, 2004.
57. North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause. 2004;11(6 pt 1):589-600.
58. Mosca L, Appel LJ, Benjamin EJ, et al; American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004;109(5):672-693.